2,4,5-三氟碘苯 | 17533-08-3

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 芳香烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4,5-三氟碘苯
• 英文名称: 1,2,4-trifluoro-5-iodobenzene
• 英文别名: 2,4,5-trifluoroiodobenzene
• CAS: 17533-08-3
• 化学式: C₆H₂F₃I
• 分子量: 257.982
• InChiKey: UPCKPWDYXMTASO-UHFFFAOYSA-N

物化性质

• 沸点：
  180℃
• 密度：
  2.078
• 闪点：
  66℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2903999090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H227,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,4,5-Trifluoroiodobenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,4,5-Trifluoroiodobenzene
CAS number: 17533-08-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H2F3I
Molecular weight: 258

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,4,5-三氟碘苯 在 甲醇 、 sodium tetrahydroborate 、 氯仿 、 palladium 10% on activated carbon 、 苄基三乙基氯化铵 、 氢气 、 双氧水 、 palladium diacetate 、 碳酸氢钠 、 三乙胺 、 D-脯氨酸 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 70.0h， 生成 (3S)-2’,4’,5’-三氟-3-羟基苯丁酸
  参考文献：
  名称：

  （R）-和（S）-3-羟基-4-（2,4,5-三氟苯基）丁酸的新颖和对映选择性合成：西他列汀及其衍生物的合成子

  摘要：

  为一个新的合成策略（[R ）-和（小号）-3-羟基-4-（2,4,5-三氟苯基）丁酸，西他列汀中和它的衍生物的制备建筑物块，被开发。Pd（OAc）2催化2,4,5-三氟-1-碘苯与烯丙醇的偶合，得到3-（2,4,5-三氟苯基）丙醛，产率为95％。1-脯氨酸催化3-苯基丙醛（仅1.2摩尔当量）与亚硝基苯反应，然后用NaBH 4还原，Pd / C催化氢化，得到（R）-3-（2,4,5-三氟苯基）丙烷-1 ，具有> 99％ee和65％收率的1,2-二醇。1,2-丙二醇单元的伯羟基选择性甲苯磺酸化，然后进行氰化物置换（R）-3-羟基-4-（2,4,5-三氟苯基）丁腈（80％）。在碱性水解下，腈以90％的产率转化为标题β-羟基酸。因此，从起始原料通过四个步骤对映选择性地制备了（R）-3-羟基-4-（2,4,5-三氟苯基）丁酸，总产率为45％。用d-脯氨酸作为催化剂重复反应序列，以45％的总收率和＞

  DOI：

  10.1016/j.tet.2012.01.095
• 作为产物：
  描述：

  2,4,5-三氟苯胺 生成 2,4,5-三氟碘苯
  参考文献：
  名称：

  芴衍生物。二十五。氟代芴。六

  摘要：

  5,6,7,8-四氟-2-乙酰氨基芴、1,4,7-三氟-2-乙酰氨基芴和 5,8-二氟-2-乙酰氨基芴的合成，1,2,3,4, 7-五-、1,2,3,4-四-、1,2,4,7-四-、1,4,7-三-和1,4-二-氟芴酮，和相关衍生物的数量与它们的红外吸收数据一起报告。具有未取代的 2（或 7）位的多氟芴酮的硝化发生在该位置。在 4,7-二氟-2-乙酰氨基芴的硝化反应中观察到了意想不到的指示效果。

  DOI：

  10.1139/v67-418

文献信息

• Gold-Catalyzed Chemoselective Couplings of Polyfluoroarenes with Aryl Germanes and Downstream Diversification
  作者：Amit Dahiya、Christoph Fricke、Franziska Schoenebeck

  DOI：10.1021/jacs.0c02860

  日期：2020.4.29

  describes the chemoselective coupling of polyfluoroarenes with aryl germanes in the presence of aromatic C-I, C-Br, C-Cl, C-OTf and C-SiMe3 groups, as well as demonstrates the further downstream diversification to give richly functionalized and highly fluorinated polyarenes. The strategy relies on an in situ Umpolung of the FnArH, followed by selective Au(I)/Au(III)-catalyzed coupling with electron-poor or

  本报告描述了在芳族 CI、C-Br、C-Cl、C-OTf 和 C-SiMe3 基团存在下多氟芳烃与芳基锗烷的化学选择性偶联，并展示了进一步的下游多样化，以提供丰富的功能化和高度氟化的聚芳烃。该策略依赖于 FnArH 的原位 Umpolung，然后选择性 Au(I)/Au(III) 催化与缺电子或富芳基锗烷偶联，即使存在具有挑战性的邻位取代基，并扩大了当前氧化金催化中与以前难以接近的缺电子/缺电子联芳基化合物的可用耦合空间。
• SYNTHESIS OF 1-(2-DEOXY-β-<scp>D</scp>- RIBOFURANOSYL)-2,4-DIFLUORO-5-SUBSTITUTED-BENZENE THYMIDINE MIMICS,^*SOME RELATED α-ANOMERS, AND THEIR EVALUATION AS ANTIVIRAL AND ANTICANCER AGENTS
  作者：Zhi-Xian Wang、Weili Duan、Leonard I. Wiebe、Jan Balzarini、Erik De Clercq、Edward E. Knaus

  DOI：10.1081/ncn-100001435

  日期：2001.2.26

  Me, F, Cl, Br, I, CF3, CN, NO2, NH2), designed as thymidine mimics, were synthesized for evaluation as anticancer and antiviral agents. The coupling reaction of 3,5-bis-O-(p-chlorobenzoyl)-2-deoxy-α-D-ribofuranosyl chloride with an organocadmium reagent [(2,4-difluorophenyl)2Cd] afforded a mixture of the α- and β-anomeric products (α:β = 3:1 to 10:1 ratio). Treatment of the α-anomer with BF3·Et2O in

  一组具有各种C-5取代基（H，Me，F，Cl，Br，I，CF3，CN，NO2，合成了设计为胸苷模拟物的NH2）作为抗癌药和抗病毒药进行评估。3,5-双-O-（对氯苯甲酰基）-2-脱氧-α-D-呋喃呋喃糖基氯与有机镉试剂[（2,4-二氟苯基）2Cd]的偶联反应得到α-和-C的混合物β-异头物产物（α：β= 3：1至10：1的比例）。作为在主要的α-端基异构体上异构化成所需的β-端基异构体的有效方法，人们开发了在BF-​​110-C中在硝基乙烷中用BF3·Et2O处理α-端基异构体的方法。相对于胸腺嘧啶（CC50 = 10-3-10），在MTT分析（CC50 = 10−3–10−4 M范围）中，5取代的（H，Me，Cl，I，NH2）β-异头物显示出可忽略的细胞毒性。 -5 M范围），针对各种癌细胞系。相比之下，5-NO2衍生物具有更高的细胞毒性（CC50 = 10-5-6-10 M范围）。使用
• [EN] NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION<br/>[FR] NOUVEAUX INHIBITEURS DE DIPEPTIDYLE PEPTIDASE IV, COMPOSITIONS PHARMACEUTIQUES EN CONTENANT, ET LEUR PROCEDE DE PREPARATION
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2006040625A1

  公开（公告）日：2006-04-20

  The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: (I) wherein Y is -S(O)m, -CH2-, CHF, or -CF2; m is 0, 1, or 2; X is a bond, C1-C5 alkyl (e.g., -CH2-), or -C(=0)-; the dotted line [----] in the carbocyclic ring represents an optional double bond; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, CN, -COOR3, CONR3R4, -OR3, -NR3R4, or NR3COR3; R2 is hydrogen, cyano, COOH, or an isostere of a carboxylic acid (such as SO3H, CONOH, B(OH)2, PO3R3R4, SO2NR3R4, tetrazole, -COOR3, -CONR3R4, NR3COR4, or -COOCOR3).

  本发明涉及一种新型化合物，其作为二肽基肽酶IV（DPP-IV）抑制剂的公式如下：(I)，其中Y为-S(O)m，-CH2-，CHF或-CF2；m为0，1或2；X为键，C1-C5烷基（例如，-CH2-），或-C(=0)-；在环状碳环中的虚线[----]表示可选的双键；R1为取代或未取代的环烷基，取代或未取代的环烷基烷基，取代或未取代的环烯基，取代或未取代的芳基，取代或未取代的芳基烷基，取代或未取代的杂芳基，取代或未取代的杂环戊基，取代或未取代的杂环烷基，取代或未取代的杂芳基烷基，CN，-COOR3，CONR3R4，-OR3，-NR3R4或NR3COR3；R2为氢，氰基，COOH或羧酸的同分异构体（例如SO3H，CONOH，B(OH)2，PO3R3R4，SO2NR3R4，四唑，-COOR3，-CONR3R4，NR3COR4或-COOCOR3）。
• [EN] TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES EN TANT QU'INHIBITEURS DE MPGES-1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2012110860A1

  公开（公告）日：2012-08-23

  The present invention relates to tricyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase- 1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthama, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. (I).

  本发明涉及式(I)的三环化合物或其药用可接受的盐，作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗各种疾病或症状引起的疼痛和/或炎症方面具有用处，如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。
• [EN] SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DE PROSTAGLANDINES À PETITES MOLÉCULES
  申请人：ALBERT EINSTEIN COLLEGE OF MEDICINE

  公开号：WO2021091823A1

  公开（公告）日：2021-05-14

  The disclosure provides compounds of Formula 1, and the pharmaceutically acceptable salts thereof. The variables in Formula 1, e.g. X1-X5, A1, A2, and R1-R4 are described herein. Such compounds are useful as prostaglandin transport (PGT) inhibitors. The disclosure further includes pharmaceutical compositions comprising a compound of Formula 1 or salt thereof and methods of using compounds of Formula 1 and salts thereof to treat diseases and disorders mediated, at least in part, by prostaglandin levels or cyclooxygenase activity. Such diseases and disorders include painful and inflammatory conditions.

  该披露提供了Formula 1的化合物及其药用盐。Formula 1中的变量，例如X1-X5，A1，A2和R1-R4在此处进行描述。这些化合物可用作前列腺素转运体（PGT）抑制剂。该披露还包括含有Formula 1的化合物或其盐的药物组合物，以及使用Formula 1的化合物和其盐来治疗至少部分由前列腺素水平或环氧化酶活性介导的疾病和疾病的方法。这些疾病和疾病包括疼痛和炎症性疾病。